Yizhong Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yizhong Zheng has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Brendon J. Yee
Woolcock Institute of Medical Research Sydney Australia
5 shared publications- Angela L. D'ROzario
CIRUS, Centre for Sleep and Chronobiology, Woolcock Institute of Medical Research, Macquarie University Sydney New South Wales Australia
2 shared publications Brendon J Yee
Woolcock Institute of Medical Research, Centre for Sleep and Chronobiology , Glebe, NSW , Australia
2 shared publications- Brendon J. Yee
Department of Respiratory & Sleep Medicine, Royal Prince Alfred Hospital
2 shared publications Craig L. Phillips
Woolcock Institute of Medical Research Sydney Australia
2 shared publicationsKeith Wong
Woolcock Institute of Medical Research Sydney Australia
2 shared publications
Latest Publications
- Open Access
- 15 July 2026
- Published by Wiley in Respirology
- Vol. 31 (9) , 866-868
GLP ‐1‐Based Therapy for Obstructive Sleep Apnoea
- 15 July 2026
- Published by Wiley in Respirology
- Vol. 31 (9) , 866-868
Open AccessGLP ‐1‐Based Therapy for Obstructive Sleep Apnoea
- 16 February 2026
- Published by Wiley in Journal of Sleep Research
- Vol. 35 (4) , e70284
Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo‐Controlled Crossover Trial
Insomnia disorder is harmful and requires novel treatments. Cannabinol, an oxidative by‐product of Δ9‐tetrahydrocannabinol, is claimed to be a hypnotic, but its effects on objective sleep and insomnia remain unknown. This randomized, double‐blind, placebo‐controlled, three‐arm, single‐night crossover trial evaluated the acute efficacy and safety of cannabinol for insomnia disorder. Twenty adults (aged 25–65) with physician‐diagnosed insomnia disorder (meeting DSM‐5 and ICSD‐3 criteria; Insomnia Severity Index ≥ 15) were enrolled at the Woolcock Institute of Medical Research (Sydney, Australia) between August 2022 and September 2023. Participants received a single 2 mL oral dose of 30 mg (1.5%) or 300 mg (15%) cannabinol, or matched placebo (2‐week washout). All participants (17 female and 3 males; mean ± SD age 42 ± 13 years) completed the protocol and were statistically analysed. The primary outcome was wake after sleep onset (WASO) minutes, measured by overnight polysomnography. Cannabinol did not significantly change WASO (300 mg: −6.3 min [95% CI: −18.2, +5.5], p = 0.29, dz = −0.22; 30 mg: −4.0 min [−15.9, +7.9], p = 0.50, dz = 0.11). However, 300 mg cannabinol increased non‐rapid eye movement‐2 sleep ( p = 0.03, dz = 0.54), subjective sleep quality ( p = 0.005, dz = 0.56); and reduced sleep onset latency ( p = 0.004, dz = −0.74) and electroencephalographic arousal indices ( p = 0.02, dz = −0.65). There were 247 mild‐to‐moderate adverse events across arms. Larger, longer trials are warranted. ClinicalTrials.gov Identifier: NCT05344170.
- 16 February 2026
- Published by Wiley in Journal of Sleep Research
- Vol. 35 (4) , e70284
Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo‐Controlled Crossover Trial
Insomnia disorder is harmful and requires novel treatments. Cannabinol, an oxidative by‐product of Δ9‐tetrahydrocannabinol, is claimed to be a hypnotic, but its effects on objective sleep and insomnia remain unknown. This randomized, double‐blind, placebo‐controlled, three‐arm, single‐night crossover trial evaluated the acute efficacy and safety of cannabinol for insomnia disorder. Twenty adults (aged 25–65) with physician‐diagnosed insomnia disorder (meeting DSM‐5 and ICSD‐3 criteria; Insomnia Severity Index ≥ 15) were enrolled at the Woolcock Institute of Medical Research (Sydney, Australia) between August 2022 and September 2023. Participants received a single 2 mL oral dose of 30 mg (1.5%) or 300 mg (15%) cannabinol, or matched placebo (2‐week washout). All participants (17 female and 3 males; mean ± SD age 42 ± 13 years) completed the protocol and were statistically analysed. The primary outcome was wake after sleep onset (WASO) minutes, measured by overnight polysomnography. Cannabinol did not significantly change WASO (300 mg: −6.3 min [95% CI: −18.2, +5.5], p = 0.29, dz = −0.22; 30 mg: −4.0 min [−15.9, +7.9], p = 0.50, dz = 0.11). However, 300 mg cannabinol increased non‐rapid eye movement‐2 sleep ( p = 0.03, dz = 0.54), subjective sleep quality ( p = 0.005, dz = 0.56); and reduced sleep onset latency ( p = 0.004, dz = −0.74) and electroencephalographic arousal indices ( p = 0.02, dz = −0.65). There were 247 mild‐to‐moderate adverse events across arms. Larger, longer trials are warranted. ClinicalTrials.gov Identifier: NCT05344170.
- 2 November 2025
- Published by Wiley in Respirology
- Vol. 31 (2) , 204-213
A Pilot Randomised Non‐Inferiority Trial of Auto‐Titrating Versus Fixed Continuous Positive Airway Pressure for Obesity Hypoventilation Syndrome With Severe Obstructive Sleep Apnoea
Background and Objective: Fixed CPAP (fCPAP) is the preferred first‐line ventilatory therapy in patients with obesity hypoventilation syndrome with severe obstructive sleep apnoea (OHS + sOSA). Auto‐titrating CPAP (APAP) is not recommended but has not been systematically evaluated in this population. Our pilot study aimed to provide feasibility data for a larger comparative effectiveness trial to determine whether APAP is non‐inferior to fCPAP for improving hypercapnic respiratory failure. Methods: Participants with OHS + sOSA were randomised to either APAP or fCPAP for 3 months. The primary outcome was the change in PaCO 2 . Secondary outcomes included changes in quality of life and cardiovascular biomarkers. A sample size of 82 was needed to demonstrate non‐inferiority of APAP compared to fCPAP (assuming a non‐inferiority margin of −2.5 mmHg). To assess feasibility we aimed to recruit up to 44 participants in this pilot trial. Results: Twenty‐eight of 84 screened participants were randomised (Mean ± SD: Age 55 ± 12.5 years, BMI 54 ± 9.9 kg m −2 , PaCO 2 49 ± 2.6 mmHg, AHI 88 ± 31 events/h) to APAP ( n = 15) or fCPAP ( n = 13). Mean adherence exceeded 4 h in both groups; however 25% of randomised participants did not complete the trial. Both treatments reduced PaCO 2 (fCPAP: −5.7 ± 1.6 mmHg, APAP: −4.1 ± 2.8 mmHg). Test of non‐inferiority for APAP versus fCPAP was inconclusive (mean ΔPaCO 2 difference = −1.7 mmHg (95% CI −5.0 to 1.6 mmHg)). Adherence and sleep quality improvements favoured fCPAP, while other outcomes were comparable. Conclusion: The pilot study highlighted important challenges with recruitment and retention. While the study is not powered to confirm the non‐inferiority of APAP, some outcomes appeared to favour fCPAP and APAP use in OHS + sOSA should be approached cautiously. A larger study with protocol modifications is required to confirm these preliminary findings. Trial Registration: ACTRN12618000379213. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=374259 . Assessing the Efficacy of Auto‐titrating versus Fixed Continuous Positive Airway Pressure in Obesity Hypoventilation Syndrome image
- 2 November 2025
- Published by Wiley in Respirology
- Vol. 31 (2) , 204-213
A Pilot Randomised Non‐Inferiority Trial of Auto‐Titrating Versus Fixed Continuous Positive Airway Pressure for Obesity Hypoventilation Syndrome With Severe Obstructive Sleep Apnoea
Background and Objective: Fixed CPAP (fCPAP) is the preferred first‐line ventilatory therapy in patients with obesity hypoventilation syndrome with severe obstructive sleep apnoea (OHS + sOSA). Auto‐titrating CPAP (APAP) is not recommended but has not been systematically evaluated in this population. Our pilot study aimed to provide feasibility data for a larger comparative effectiveness trial to determine whether APAP is non‐inferior to fCPAP for improving hypercapnic respiratory failure. Methods: Participants with OHS + sOSA were randomised to either APAP or fCPAP for 3 months. The primary outcome was the change in PaCO 2 . Secondary outcomes included changes in quality of life and cardiovascular biomarkers. A sample size of 82 was needed to demonstrate non‐inferiority of APAP compared to fCPAP (assuming a non‐inferiority margin of −2.5 mmHg). To assess feasibility we aimed to recruit up to 44 participants in this pilot trial. Results: Twenty‐eight of 84 screened participants were randomised (Mean ± SD: Age 55 ± 12.5 years, BMI 54 ± 9.9 kg m −2 , PaCO 2 49 ± 2.6 mmHg, AHI 88 ± 31 events/h) to APAP ( n = 15) or fCPAP ( n = 13). Mean adherence exceeded 4 h in both groups; however 25% of randomised participants did not complete the trial. Both treatments reduced PaCO 2 (fCPAP: −5.7 ± 1.6 mmHg, APAP: −4.1 ± 2.8 mmHg). Test of non‐inferiority for APAP versus fCPAP was inconclusive (mean ΔPaCO 2 difference = −1.7 mmHg (95% CI −5.0 to 1.6 mmHg)). Adherence and sleep quality improvements favoured fCPAP, while other outcomes were comparable. Conclusion: The pilot study highlighted important challenges with recruitment and retention. While the study is not powered to confirm the non‐inferiority of APAP, some outcomes appeared to favour fCPAP and APAP use in OHS + sOSA should be approached cautiously. A larger study with protocol modifications is required to confirm these preliminary findings. Trial Registration: ACTRN12618000379213. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=374259 . Assessing the Efficacy of Auto‐titrating versus Fixed Continuous Positive Airway Pressure in Obesity Hypoventilation Syndrome image
- Open Access
- 1 October 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (10) , 1467-1468
Unmasking Obesity Hypoventilation Syndrome Trajectories: Clustering Patient Journeys in Real-World Noninvasive Ventilation Use
- 1 October 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (10) , 1467-1468
Open AccessUnmasking Obesity Hypoventilation Syndrome Trajectories: Clustering Patient Journeys in Real-World Noninvasive Ventilation Use
- Open Access
- 1 October 2024
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 20 (3) , 230235
Management of central sleep apnoea: a review of non-hypercapnic causes
Central sleep apnoea (CSA) is characterised by recurrent episodes of airway cessation or reduction in the absence of respiratory effort. Although CSA is less common than obstructive sleep apnoea, it shares similar symptoms. CSA can be secondary to various medical conditions, high altitude and medication exposure. CSA can also emerge during obstructive sleep apnoea therapy. There are a range of treatment options and selecting the right therapy requires an understanding of the pathophysiology of CSA. This review explores the aetiology, pathophysiology and clinical management of non-hypercapnic CSA.
- 1 October 2024
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 20 (3) , 230235
Open AccessManagement of central sleep apnoea: a review of non-hypercapnic causes
Central sleep apnoea (CSA) is characterised by recurrent episodes of airway cessation or reduction in the absence of respiratory effort. Although CSA is less common than obstructive sleep apnoea, it shares similar symptoms. CSA can be secondary to various medical conditions, high altitude and medication exposure. CSA can also emerge during obstructive sleep apnoea therapy. There are a range of treatment options and selecting the right therapy requires an understanding of the pathophysiology of CSA. This review explores the aetiology, pathophysiology and clinical management of non-hypercapnic CSA.
- Open Access
- 23 February 2024
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 47 (6)
Electroencephalographic slowing during REM sleep in older adults with subjective cognitive impairment and mild cognitive impairment
Study Objectives: In older adults with Alzheimer’s disease, slowing of electroencephalographic (EEG) activity during REM sleep has been observed. Few studies have examined EEG slowing during REM in those with mild cognitive impairment (MCI) and none have examined its relationship with cognition in this at-risk population. Methods: Two hundred and ten older adults (mean age = 67.0, SD = 8.2 years) underwent comprehensive neuropsychological, medical, and psychiatric assessment and overnight polysomnography. Participants were classified as subjective cognitive impairment (SCI; n = 75), non-amnestic MCI (naMCI, n = 85), and amnestic MCI (aMCI, n = 50). REM EEG slowing was defined as (δ + θ)/(α + σ + β) power and calculated for frontal, central, parietal, and occipital regions. Analysis of variance compared REM EEG slowing between groups. Correlations between REM EEG slowing and cognition, including learning and memory, visuospatial and executive functions, were examined within each subgroup. Results: The aMCI group had significantly greater REM EEG slowing in the parietal and occipital regions compared to the naMCI and SCI groups (partial η2 = 0.06, p < 0.05 and 0.06, p < 0.05, respectively), and greater EEG slowing in the central region compared to SCI group (partial η2 = 0.03, p < 0.05). Greater REM EEG slowing in parietal (r = −0.49) and occipital regions (r = −0.38 [O1/M2] and −0.33 [O2/M1]) were associated with poorer visuospatial performance in naMCI. Conclusions: REM EEG slowing may differentiate older adults with memory impairment from those without. Longitudinal studies are now warranted to examine the prognostic utility of REM EEG slowing for cognitive and dementia trajectories.
- 23 February 2024
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 47 (6)
Open AccessElectroencephalographic slowing during REM sleep in older adults with subjective cognitive impairment and mild cognitive impairment
Study Objectives: In older adults with Alzheimer’s disease, slowing of electroencephalographic (EEG) activity during REM sleep has been observed. Few studies have examined EEG slowing during REM in those with mild cognitive impairment (MCI) and none have examined its relationship with cognition in this at-risk population. Methods: Two hundred and ten older adults (mean age = 67.0, SD = 8.2 years) underwent comprehensive neuropsychological, medical, and psychiatric assessment and overnight polysomnography. Participants were classified as subjective cognitive impairment (SCI; n = 75), non-amnestic MCI (naMCI, n = 85), and amnestic MCI (aMCI, n = 50). REM EEG slowing was defined as (δ + θ)/(α + σ + β) power and calculated for frontal, central, parietal, and occipital regions. Analysis of variance compared REM EEG slowing between groups. Correlations between REM EEG slowing and cognition, including learning and memory, visuospatial and executive functions, were examined within each subgroup. Results: The aMCI group had significantly greater REM EEG slowing in the parietal and occipital regions compared to the naMCI and SCI groups (partial η2 = 0.06, p < 0.05 and 0.06, p < 0.05, respectively), and greater EEG slowing in the central region compared to SCI group (partial η2 = 0.03, p < 0.05). Greater REM EEG slowing in parietal (r = −0.49) and occipital regions (r = −0.38 [O1/M2] and −0.33 [O2/M1]) were associated with poorer visuospatial performance in naMCI. Conclusions: REM EEG slowing may differentiate older adults with memory impairment from those without. Longitudinal studies are now warranted to examine the prognostic utility of REM EEG slowing for cognitive and dementia trajectories.
- Open Access
- 1 January 2024
- Published by Oxford University Press (OUP) in SLEEP Advances
- Vol. 5 (1) , zpae016
A comparison of two obesity-related hypoventilation disorders: Impact on sleep, quality of life and neurocognitive outcomes and the effects of positive airway pressure therapy
Symptom impact and neurocognitive function have not been previously compared between patients with obesity-associated hypoventilation disorders (obesity hypoventilation syndrome [OHS]) and hypoventilation in the setting of obesity and obstructive airways disease (OHAD). The aim of this study is to compare baseline sleep-related symptoms, health-related quality of life, and neurocognitive function between OHS and OHAD and the impact of PAP therapy on these outcomes. Epworth Sleepiness Scale (ESS), Pittsburgh Sleepiness Quality Index (PSQI), SF36, and various neurocognitive tests, in addition to anthropometric, polysomnography, lung function, and blood gas data from participants with OHS and participants with OHAD, were included in the analysis. These data were originally collected in their respective randomized clinical trials, comparing the efficacy of different PAP modes (bilevel PAP vs. CPAP) in resolving hypercapnia. Between groups (OHS vs OHAD), pre- and post-treatment (with 3 months of positive airway pressure) comparisons were made using linear mixed modeling. 45 OHS participants (mean age 51 years old, 33% female, BMI 52 kg/m2, FER 0.81, PaCO2 54 mmHg, AHI 87/h) and 32 OHAD participants (mean age 61years old, 31% female, BMI 43kg/m2, FER 0.60, PaCO2 54 mmHg, AHI 59/h) were included in the analysis. Both OHS and OHAD had similar baseline ESS (14(5.6) vs. 12(5.4)), Global PSQI (10(3.2) vs. 11(4.8)), SF36 and neurocognitive test performances (other than OHAD had lower digit symbol substitution test performance). Treatment with PAP therapy resulted in similar ESS, Global PSQI, and SF36 improvements in both groups. Neurocognitive performance did not significantly improve after PAP therapy in either group. The symptom impact between two separate hypoventilation disorders (OHS and OHAD), in terms of sleepiness, sleep quality, quality of life, and cognitive function, were similar. OHS and OHAD had similar treatment responses in these parameters after 3 months of PAP therapy. Nocturnal ventilatory support in OHS.
- 1 January 2024
- Published by Oxford University Press (OUP) in SLEEP Advances
- Vol. 5 (1) , zpae016
Open AccessA comparison of two obesity-related hypoventilation disorders: Impact on sleep, quality of life and neurocognitive outcomes and the effects of positive airway pressure therapy
Symptom impact and neurocognitive function have not been previously compared between patients with obesity-associated hypoventilation disorders (obesity hypoventilation syndrome [OHS]) and hypoventilation in the setting of obesity and obstructive airways disease (OHAD). The aim of this study is to compare baseline sleep-related symptoms, health-related quality of life, and neurocognitive function between OHS and OHAD and the impact of PAP therapy on these outcomes. Epworth Sleepiness Scale (ESS), Pittsburgh Sleepiness Quality Index (PSQI), SF36, and various neurocognitive tests, in addition to anthropometric, polysomnography, lung function, and blood gas data from participants with OHS and participants with OHAD, were included in the analysis. These data were originally collected in their respective randomized clinical trials, comparing the efficacy of different PAP modes (bilevel PAP vs. CPAP) in resolving hypercapnia. Between groups (OHS vs OHAD), pre- and post-treatment (with 3 months of positive airway pressure) comparisons were made using linear mixed modeling. 45 OHS participants (mean age 51 years old, 33% female, BMI 52 kg/m2, FER 0.81, PaCO2 54 mmHg, AHI 87/h) and 32 OHAD participants (mean age 61years old, 31% female, BMI 43kg/m2, FER 0.60, PaCO2 54 mmHg, AHI 59/h) were included in the analysis. Both OHS and OHAD had similar baseline ESS (14(5.6) vs. 12(5.4)), Global PSQI (10(3.2) vs. 11(4.8)), SF36 and neurocognitive test performances (other than OHAD had lower digit symbol substitution test performance). Treatment with PAP therapy resulted in similar ESS, Global PSQI, and SF36 improvements in both groups. Neurocognitive performance did not significantly improve after PAP therapy in either group. The symptom impact between two separate hypoventilation disorders (OHS and OHAD), in terms of sleepiness, sleep quality, quality of life, and cognitive function, were similar. OHS and OHAD had similar treatment responses in these parameters after 3 months of PAP therapy. Nocturnal ventilatory support in OHS.
- 12 September 2023
- Published by Wiley in Respirology
- Vol. 28 (11) , 980-982
Sleep well with home automation
- 12 September 2023
- Published by Wiley in Respirology
- Vol. 28 (11) , 980-982
Sleep well with home automation
- 1 December 2021
- Published by Elsevier in Sleep Medicine Reviews
- Vol. 60, 101530
Cardiovascular disease in obesity hypoventilation syndrome – A review of potential mechanisms and effects of therapy
- 1 December 2021
- Published by Elsevier in Sleep Medicine Reviews
- Vol. 60, 101530
Cardiovascular disease in obesity hypoventilation syndrome – A review of potential mechanisms and effects of therapy